| Name | Title | Contact Details |
|---|
Gen-Diagnostics Incorporated is a San Juan Capistrano, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Iowa Health Syst Poison Cntrl is a Sioux City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fresno Surgical Hospital (FSH) is a fully-licensed, Joint Commission-accredited hospital that delivers award-winning surgical care and patient satisfaction. We are a physician-owned hospital that focuses solely on providing advanced, affordable surgical care. Each year, FSH serves approximately 12,000 patients in our Central California service area including: Fresno, Madera, Merced, Kings and Tulare Counties. Our patients enjoy a non-traditional, hotel-like setting and a commitment to quality care and patient satisfaction. Twenty-seven private inpatient suites give patients and their families an environment that promotes relaxation, comfort and healing. FSH was founded by two orthopedic surgeons, Alan H. Pierrot, MD and Thomas Thaxter, MD, who had a vision of improving healthcare. Originally named Fresno Surgery Center (FSC), the facility opened as an outpatient surgery center in 1984. Within the first year, FSC was in the top 10 percent of all freestanding outpatient surgery centers in the nation, based on the number of patients served. The center`s approach to patient service was also unique. The rare combination of compassion, hospitality and surgical excellence continues to be our distinguishing factor. We were the first facility in the United States to provide elective surgery and post-surgical care in a non-hospital setting. Overwhelming popularity among patients, surgeons and staff established FSC as the leader in the nationwide trend toward elective surgery facilities. In fact, we have consistently been recognized as a top performer both in the state of California and nationally.
Mallory Safety is a company that provides safety products and services to customers, including supply chain solutions, vending, staffing, consolidation, and technical product ownership cost savings.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.